Madrigal Pharmaceuticals (NASDAQ:MDGL) is set to give its latest quarterly earnings report on Thursday, 2026-02-19. Here's what investors need to know before the announcement.

Analysts estimate that Madrigal Pharmaceuticals will report an earnings per share (EPS) of $-0.52.

Madrigal Pharmaceuticals bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.

New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).

Earnings Track Record

Last quarter the company missed EPS by $3.09, which was followed by a 7.02% increase in the share price the next day.

Here's a look at Madrigal Pharmaceuticals's past performance and the resulting price change:

Quarter	Q3 2025	Q2 2025	Q1 2025	Q4 2024
EPS Estimate	-1.99	-3.52	-3.79	-4.12
EPS Actual	-5.08	-1.90	-3.32	-2.71
Price Change %	7.00	0.00	-4.00	-6.00

Madrigal Pharmaceuticals Share Price Analysis

Shares of Madrigal Pharmaceuticals were trading at $487.32 as of February 17. Over the last 52-week period, shares are up 38.69%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release.

Analysts' Take on Madrigal Pharmaceuticals

Understanding market sentiments and expectations within the industry is crucial for investors. This analysis delves into the latest insights on Madrigal Pharmaceuticals.

With analyst ratings, Madrigal Pharmaceuticals has a consensus rating of . The average one-year price target is $, indicating a potential .

To track all earnings releases for Madrigal Pharmaceuticals visit their earnings calendar on our site.

This article was generated by Benzinga's automated content engine and reviewed by an editor.